Alpha¹ by KaimenConfidential

Kaimen Rigor review

Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.

Musiime V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, Mujuru HA, Kityo CM, Lugemwa A, Doerholt K, Chabala C, Makumbi S, Mulenga V, McIlleron H, Burger D, Natukunda E, Shakeshaft C, Linda KJ, Nathoo K, Monkiewicz L, Yawe I, Kapasa M, Nyathi M, Lungu J, Nduna B, Ndebele W, South A, Mwamabazi M, Musoro G, Griffiths A, Zyambo K, Nazzinda R, Zimba K, Zhang Y, Walker S, Turkova A, Walker AS, Bamford A, Gibb DM, CHAPAS-4 Trial Team

DOI: 10.1056/NEJMoa2404597
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-22

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/3af7ead5-d707-4892-8145-c21a19bbd57e is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 8 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is virological suppression (viral load <400 copies/mL) at week 96, which is a surrogate marker for clinical outcomes such as disease progression and mortality. The manuscript does not provide evidence linking this surrogate to hard clinical outcomes in this pediatric population, nor does it demonstrate target engagement (e.g., PK/PD) at the tested doses. The claim of 'effective' is based on this surrogate without a validated surrogate-to-clinical-outcome link.
“Primary endpoint was week-96 viral load (VL)<400copies/mL”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are small absolute differences in virological suppression (e.g., +6.3% for TAF vs SOC, +9.7% for DTG vs LPV/r+ATV/r) and are not anchored to a minimal clinically important difference or to clinical meaningfulness. The manuscript does not state what magnitude of difference would be clinically meaningful, and the differences are presented as statistically significant without explicit clinical interpretation.
“TAF/FTC was superior to SOC (adjusted difference [95% CI] VL<400copies/mL +6.3%[2.0%,10.6%],p=0.004)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit3 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-designed and rigorously reported randomized clinical trial (CHAPAS-4) with strong methodology across most dimensions: clear scientific premise, robust study design, adequate reporting of biological variables, ethics, key resources, statistics, and transparency. The main weakness is the lack of a formal data availability statement and repository deposit, which is a common but important reporting gap for a data-driven clinical trial.

This is a post-publication audit of a published randomized controlled trial. Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence required reconciliation. The statistics verification covered only a subset of reported tests (7 of many), and the citation check found no retracted or unresolved references. The integrity check flagged minor internal inconsistencies (e.g., SAE percentage 3% vs 3.2%) that are not validity threats.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 7 tests: 7 consistent, 0 inconsistent; 7 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .004 · recomputed p = .004Reviewer 1
Primary backbone comparison: TAF vs SOC at week-96 VL<400 copies/mL
“At week-96, 406/454(89.4%) TAF/FTC vs. 378/454(83.3%) SOC had VL <400copies/mL (adjusted difference +6.3% [95% confidence interval (CI) +2.0%,+10.6%]; p=0.004)”
Find in source
Taken as given: The adjusted difference is 6.3% (0.063) with 95% CI 2.0% to 10.6%.; The p-value is two-sided from a logistic regression model.; The CI is a 95% confidence interval.
Method: Recomputed p-value from the reported estimate and 95% CI using the normal approximation (pCI function).
How we recomputed it: pCI(0.063, 0.020, 0.106, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary anchor comparison: DTG vs LPV/r+ATV/r combined at week-96 VL<400 copies/mL
“DTG was superior to LPV/r and ATV/r arms combined (adjusted difference +9.7% [95%CI +4.8%,+14.5%]; p<0.001).”
Find in source
Taken as given: The adjusted difference is 9.7% (0.097) with 95% CI 4.8% to 14.5%.; The p-value is two-sided from a logistic regression model.; The CI is a 95% confidence interval.
Method: Recomputed p-value from the reported estimate and 95% CI using the normal approximation (pCI function).
How we recomputed it: pCI(0.097, 0.048, 0.145, 0)
CONSISTENTreported p = .040 · recomputed p = .040Reviewer 1
Secondary anchor comparison: DRV/r vs LPV/r+ATV/r combined at week-96 VL<400 copies/mL
“DRV/r was not superior to LPV/r and ATV/r combined as the comparison did not meet pre-specified significance (adjusted difference +5.6% [+0.3%,+11.0%]; p=0.04 vs. threshold p=0.03 from multiple comparisons).”
Find in source
Taken as given: The adjusted difference is 5.6% (0.056) with 95% CI 0.3% to 11.0%.; The p-value is two-sided from a logistic regression model.; The CI is a 95% confidence interval.
Method: Recomputed p-value from the reported estimate and 95% CI using the normal approximation (pCI function).
How we recomputed it: pCI(0.056, 0.003, 0.110, 0)
CONSISTENTreported p = .004 · recomputed p = .004Reviewer 2
Backbone primary endpoint: TAF/FTC vs SOC difference in VL<400 at week 96
“At week-96, 406/454(89.4%) TAF/FTC vs. 378/454(83.3%) SOC had VL <400copies/mL (adjusted difference +6.3% [95% confidence interval (CI) +2.0%,+10.6%]; p=0.004)”
Find in source
Taken as given: The adjusted difference is 0.063 (6.3%); The 95% CI is (0.020, 0.106); The p-value is two-sided from a normal approximation using the CI
Method: Recomputed p from estimate and CI using normal approximation (pCI).
How we recomputed it: pCI(0.063, 0.020, 0.106, 0)
CONSISTENTreported p = .001 · recomputed p = <.001Reviewer 2
Anchor primary endpoint: DTG vs LPV/r+ATV/r combined difference in VL<400 at week 96
“DTG was superior to LPV/r and ATV/r arms combined (adjusted difference +9.7% [95%CI +4.8%,+14.5%]; p<0.001)”
Find in source
Taken as given: The adjusted difference is 0.097 (9.7%); The 95% CI is (0.048, 0.145); The p-value is two-sided from a normal approximation using the CI
Method: Recomputed p from estimate and CI using normal approximation (pCI).
How we recomputed it: pCI(0.097, 0.048, 0.145, 0)
CONSISTENTreported p = .040 · recomputed p = .040Reviewer 2
Anchor primary endpoint: DRV/r vs LPV/r+ATV/r combined difference in VL<400 at week 96
“DRV/r was not superior to LPV/r and ATV/r combined as the comparison did not meet pre-specified significance (adjusted difference +5.6% [+0.3%,+11.0%]; p=0.04 vs. threshold p=0.03 from multiple comparisons).”
Find in source
Taken as given: The adjusted difference is 0.056 (5.6%); The 95% CI is (0.003, 0.110); The p-value is two-sided from a normal approximation using the CI
Method: Recomputed p from estimate and CI using normal approximation (pCI).
How we recomputed it: pCI(0.056, 0.003, 0.110, 0)
CONSISTENTreported p = .330 · recomputed p = .327Reviewer 2
Anchor non-inferiority: ATV/r vs LPV/r difference in VL<400 at week 96
“ATV/r was non-inferior to LPV/r (adjusted difference +3.4% [-3.4%,+10.2%]; p=0.33).”
Find in source
Taken as given: The adjusted difference is 0.034 (3.4%); The 95% CI is (-0.034, 0.102); The p-value is two-sided from a normal approximation using the CI
Method: Recomputed p from estimate and CI using normal approximation (pCI).
How we recomputed it: pCI(0.034, -0.034, 0.102, 0)

lowinternal contradiction
The abstract states 'DRV/r was not superior (+5.6%[+0.3%,+11.0%],p=0.04 vs. multiple-comparison adjusted threshold p=0.03)' but the results section says 'p=0.04 vs. threshold p=0.03 from multiple comparisons'. This is consistent, but the abstract's phrasing 'not superior' might be misinterpreted as a negative result when it is actually a borderline non-significant result.
“DRV/r was not superior (+5.6%[+0.3%,+11.0%],p=0.04 vs. multiple-comparison adjusted threshold p=0.03)”
AbstractFind in source
lowinternal contradiction
The abstract states '29(3%) had serious adverse events' while Table 2 shows 29 (3.2%) with 31 events. The percentage differs slightly (3% vs 3.2%).
Abstract: '29(3%) had serious adverse events'; Table 2: 'Serious adverse event 14 (3.0%) 14 | 15 (3.3%) 17 | ... | 29 (3.2%) 31'
Table 2reviewer’s wording
lowinternal contradiction
The abstract reports '497(54.1%) male' while Table 1 shows '497 (54.1%)' for total male, consistent. No issue.
Abstract: '497(54.1%) male'; Table 1: 'Male ... 497 (54.1%)'
Table 1reviewer’s wording

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

5 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewers 1, 2
TAF/FTC is superior to SOC for virological suppression at week-96.
The primary endpoint analysis shows a statistically significant adjusted difference of +6.3% (95% CI 2.0-10.6%, p=0.004), supporting superiority.
Evidence: Adjusted difference +6.3% [95% CI +2.0%,+10.6%]; p=0.004
“At week-96, 406/454(89.4%) TAF/FTC vs. 378/454(83.3%) SOC had VL <400copies/mL (adjusted difference +6.3% [95% confidence interval (CI) +2.0%,+10.6%]; p=0.004)”
ResultsFind in source
supportedReviewers 1, 2
DTG is superior to LPV/r and ATV/r combined for virological suppression.
The pre-specified comparison shows a statistically significant adjusted difference of +9.7% (95% CI 4.8-14.5%, p<0.001), supporting superiority.
Evidence: Adjusted difference +9.7% [95%CI +4.8%,+14.5%]; p<0.001
“DTG was superior to LPV/r and ATV/r arms combined (adjusted difference +9.7% [95%CI +4.8%,+14.5%]; p<0.001).”
ResultsFind in source
supportedReviewers 1, 2
DRV/r is not superior to LPV/r and ATV/r combined.
The adjusted difference of +5.6% (95% CI 0.3-11.0%) has p=0.04, which does not meet the pre-specified multiple-comparison threshold of p=0.03, so the claim of non-superiority is supported.
Evidence: Adjusted difference +5.6% [+0.3%,+11.0%]; p=0.04 vs. threshold p=0.03
“DRV/r was not superior to LPV/r and ATV/r combined as the comparison did not meet pre-specified significance (adjusted difference +5.6% [+0.3%,+11.0%]; p=0.04 vs. threshold p=0.03 from multiple comparisons).”
ResultsFind in source
supportedReviewers 1, 2
ATV/r is non-inferior to LPV/r.
The adjusted difference of +3.4% (95% CI -3.4% to +10.2%) is within the pre-specified 12% non-inferiority margin, supporting non-inferiority.
Evidence: Adjusted difference +3.4% [-3.4%,+10.2%]; p=0.33
“ATV/r was non-inferior to LPV/r (adjusted difference +3.4% [-3.4%,+10.2%]; p=0.33).”
ResultsFind in source
supportedReviewers 1, 2
Second-line ART including TAF/FTC and DTG are effective for children without evident safety concerns.
The trial demonstrates superior virological suppression with TAF/FTC and DTG, with no significant safety differences across arms, supporting the claim.
Evidence: Primary and secondary outcomes show efficacy and safety; only one death and no between-arm differences in serious AEs.
“Second-line ART including TAF/FTC and DTG are effective for children without evident safety concerns.”
ConclusionFind in source

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy endpoint is virological suppression (viral load <400 copies/mL) at week 96, which is a surrogate marker for clinical outcomes such as disease progression and mortality. The manuscript does not provide evidence linking this surrogate to hard clinical outcomes in this pediatric population, nor does it demonstrate target engagement (e.g., PK/PD) at the tested doses. The claim of 'effective' is based on this surrogate without a validated surrogate-to-clinical-outcome link.
“Primary endpoint was week-96 viral load (VL)<400copies/mL”
Find in source
INADEQUATEEffect size
The reported effect sizes are small absolute differences in virological suppression (e.g., +6.3% for TAF vs SOC, +9.7% for DTG vs LPV/r+ATV/r) and are not anchored to a minimal clinically important difference or to clinical meaningfulness. The manuscript does not state what magnitude of difference would be clinically meaningful, and the differences are presented as statistically significant without explicit clinical interpretation.
“TAF/FTC was superior to SOC (adjusted difference [95% CI] VL<400copies/mL +6.3%[2.0%,10.6%],p=0.004)”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on pediatric ART, TAF, DTG, and boosted PIs, acknowledging gaps in pediatric data. The rationale for comparing TAF vs SOC and different anchor drugs is clearly linked to the study objectives. Limitations of prior research (e.g., small single-arm trials, adult data) are addressed by the trial's design and discussion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the trial.

Evidence

“There are minimal data on TAF in African children; the first paediatric pharmacokinetic data showed tenofovir concentrations equivalent to those safe and effective in adults.”

Introduction ¶1Find in source

“CHAPAS-4 compared efficacy, safety and tolerability of different second-line anchor drugs combined with TAF-based or SOC backbone in African children aged 3-15 years.”

Introduction ¶4Find in source

“concerns about bone and renal toxicity and lack of paediatric formulations limit paediatric TDF use.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

“A tenofovir disoproxil fumarate (TDF)-based backbone is recommended for first and second-line ART for adolescents >30kg; INSTI-based regimens including tenofovir demonstrate robust efficacy when compared to ritonavir-boosted PI-based regimens including zidovudine in adult second-line trials.”

Introduction ¶1Find in source

“There are minimal data on TAF in African children; the first paediatric pharmacokinetic data showed tenofovir concentrations equivalent to those safe and effective in adults.”

Introduction ¶3Find in source

“The superior virological suppression of 89.4% at 96 weeks observed with TAF/FTC is comparable to the 93-100% reported in four small single-arm paediatric trials of TAF.”

Discussion ¶2Find in source

Randomization method (computer-generated permuted blocks) and unit (individual child) are clearly described. The open-label design is stated with a rationale (objective primary endpoint). Power analysis is provided for both backbone and anchor comparisons. Inclusion/exclusion criteria are pre-specified. Outlier handling is addressed via ITT and per-protocol analyses. Controls are inherent in the factorial design (comparator arms). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding (open-label with rationale), power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“A computer-generated sequential randomisation list with variably sized permuted blocks was prepared by the trial statistician and incorporated securely into an online database.”

Methods ¶3Find in source

“For the backbone randomisation, assuming 80.0%-87.5% SOC achieved VL<400 copies/ml at week-96, 920 children provided ≥95% power to demonstrate TAF was non-inferior (10% margin) (two-sided alpha=0.05), assuming 2.5% loss-to-follow-up”

Methods ¶6Find in source

“The open-label design of the trial could have potentially introduced bias; however the primary endpoint (VL) was objective.”

Discussion ¶8Find in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding (open-label with rationale), power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“A computer-generated sequential randomisation list with variably sized permuted blocks was prepared by the trial statistician and incorporated securely into an online database.”

Methods ¶3Find in source

“The open-label design of the trial could have potentially introduced bias; however the primary endpoint (VL) was objective.”

Discussion ¶8Find in source

paraphrase[Methods, paragraph 5]

Sex is reported (54.1% male). Age, weight, height, BMI, CD4 count, and WHO stage are reported in baseline table. Demographics include age, sex, and clinical characteristics. Species/strain and housing are not applicable for a human trial. Sex justification is not applicable as both sexes are enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, and health status.

Evidence

“497(54.1%) children were male; median age 10 years (IQR 8,13)”

Results ¶1Find in source

paraphrase[Table 1]

“Weight-for-age Z-score -1.6 (-2.4, -0.9)”

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, and health status.

Evidence

“497(54.1%) children were male; median age 10 years (IQR 8,13)”

Results ¶1Find in source

paraphrase[Table 1]

“Weight (kg) 26.1 (20.2, 33.5) ... CD4 (cells/mm^3) 667 (405, 963) ... VL (copies/ml) 17909 (5417, 58359)”

paraphrase[Table 1]

“WHO stage 1 244 (52.9%) ... 4 14 (3.0%)”

The trial was approved by named ethics committees in Uganda, Zambia, Zimbabwe, and UK. Informed consent and assent are described. Regulatory compliance is implied by adherence to national guidelines and the Declaration of Helsinki (not explicitly named but implied).

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

paraphrase[Methods, paragraph 2]

“The trial was approved by ethics committees in Uganda, Zambia, Zimbabwe, and UK (protocol: www.mrcctu.ucl.ac.uk/studies/all-studies/c/chapas-4)”

“Guardians provided written informed consent, with additional assent from older children, according to national guidelines.”

Methods ¶2Find in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

paraphrase[Methods, paragraph 2]

“The trial was approved by ethics committees in Uganda, Zambia, Zimbabwe, and UK (protocol: www.mrcctu.ucl.ac.uk/studies/all-studies/c/chapas-4)”

“Guardians provided written informed consent, with additional assent from older children, according to national guidelines.”

Methods ¶2Find in source

paraphrase[Ethical approval section]

“The trial was approved by ethics committees in Uganda (Joint Research Ethics Committee (JREC)), Zambia (University of Zambia Biomedical Research Ethics Committee (UNZABREC)), Zimbabwe (Joint Research Ethics Committee University of...”

The investigational drugs (TAF/FTC, ABC/3TC, ZDV/3TC, DTG, DRV/r, ATV/r, LPV/r) are named with manufacturers (e.g., Gilead, ViiV, Janssen). Doses and regimens are implied. Statistical software (Stata version 17.0) is identified. Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources, including investigational drugs and software, are adequately identified.

Evidence

“Participants were randomised to one of two backbones (TAF/FTC or standard-of-care (SOC) (abacavir (ABC)/3TC or ZDV/3TC, whichever not used first-line)) and simultaneously to one of four anchor drugs (DTG, DRV/r, ATV/r, LPV/r).”

Methods ¶3Find in source

“Analyses were intention-to-treat using Stata (version 17.0).”

Methods ¶7Find in source

PASSReviewer 2· 85% conf

Key resources, primarily the investigational drugs, are adequately identified.

Evidence

“European Developing Country Clinical Trial Partnership (funder), and pharmaceutical companies donating additional funding (Gilead Sciences, Johnson and Johnson) and drugs (ViiV Healthcare, Gilead Sciences, Johnson and Johnson, CIPLA)”

Methods ¶6Find in source

“Analyses were intention-to-treat using Stata (version 17.0).”

Methods ¶5Find in source

Statistical tests are named (logistic regression, Cox regression, GEE). Assumptions are handled by design (ITT, per-protocol). Exact p-values are reported (e.g., p=0.004). Effect sizes with 95% CIs are reported. Software is identified. Data presentation includes per-group n and CIs. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with CIs, and appropriate data presentation.

Evidence

“Primary endpoint analyses used logistic regression (adjusting for stratification factors), then marginal estimation of risk differences.”

Methods ¶7Find in source

“At week-96, 406/454(89.4%) TAF/FTC vs. 378/454(83.3%) SOC had VL <400copies/mL (adjusted difference +6.3% [95% confidence interval (CI) +2.0%,+10.6%]; p=0.004)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with CIs, and appropriate data presentation.

Evidence

“Primary endpoint analyses used logistic regression (adjusting for stratification factors), then marginal estimation of risk differences.”

Methods ¶5Find in source

“adjusted difference +6.3% [95% confidence interval (CI) +2.0%,+10.6%]; p=0.004”

ResultsFind in source

“DTG was superior to LPV/r and ATV/r arms combined (adjusted difference +9.7% [95%CI +4.8%,+14.5%]; p<0.001)”

ResultsFind in source

No data availability statement is present. The protocol is available at a URL, but raw data are not deposited in a public repository. For a clinical trial, managed access is acceptable, but no mechanism is described. Code sharing is not applicable as no custom code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability is not explicitly stated; the paper mentions a protocol URL but no data sharing statement.

Evidence

absence[Entire paper]

No data availability statement is present.

“protocol: www.mrcctu.ucl.ac.uk/studies/all-studies/c/chapas-4”

Methods ¶2Find in source

WARNReviewer 2· 80% conf

Data availability is mentioned but not fully concrete; no repository deposit or code sharing.

Evidence

“Full study details can be found in the protocol at nejm.org.”

Methods ¶2Find in source

absence[End of paper]

No data availability statement found.

Trial is registered (ISRCTN22964075). Reporting guideline (CONSORT) is implied by the CONSORT flow diagram. All pre-specified outcomes are reported. Limitations are discussed (open-label, generalisability). Conclusions are proportional to evidence. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“(ISRCTN22964075)”

AbstractFind in source

“The open-label design of the trial could have potentially introduced bias; however the primary endpoint (VL) was objective.”

Discussion ¶8Find in source

“The main funding for this study is provided by the European and Developing Countries Clinical Trials Partnership.”

FundingFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, limitations discussed, and conclusions proportional.

Evidence

“(ISRCTN22964075)”

AbstractFind in source

“A limitation is that CHAPAS-4 does not provide direct evidence to inform anchor/backbone choice in this situation; however, safety and efficacy could be inferred (given lack of evidence of interaction) and they will undoubtedly remain important future options.”

Discussion ¶8Find in source

“The CHAPAS-4 trial was sponsored by University College London (UCL), with central management by the Medical Research Council (MRC) Clinical Trials Unit at UCL supported by MRC core funding (MC_UU_00004/03).”

FundingFind in source

Registered (1 ID: ISRCTN). Reporting guideline cited: CONSORT.

ISRCTN

ISRCTN22964075

Reporting guidelines: CONSORT

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 22 references by DOI: 19 verified — 3 no DOI (shown, not verified).

NO DOI
Dolutegravir with recycled NRTIs is noninferior to PI-based ART: VISEND trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Priorities for antiretroviral drug optimization in adults and children: report of a CADO, PADO and HIVResNet joint meeting, 27 September–15 October 2021
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly typo, consistency, grammar.

MINORtypoAbstract, Results
“17,573copies/ml[5,549-55,700]”
→ Add space: '17,573 copies/ml [5,549-55,700]'
Missing space before bracket.
MINORconsistencyMethods, paragraph 2
“protocol: www.mrcctu.ucl.ac.uk/studies/all-studies/c/chapas-4 (http://www.mrcctu.ucl.ac.uk/studies/all-studies/c/chapas-4)”
→ Use a single URL format.
Duplicate URL with and without http.
MINORgrammarDiscussion, paragraph 4
“These findings, alongside the additional benefits of smaller pill size, once-daily administration, lower cost and lower risk of hypersensitivity, make TAF a valuable second-line option.”
→ Consider rephrasing for clarity: 'These findings, along with the additional benefits of smaller pill size, once-daily administration, lower cost, and lower risk of hypersensitivity, make TAF a valuable second-line option.'
Minor punctuation.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and the findings are well-supported. An informed reader should weigh the absence of a data availability statement and the minor internal inconsistencies (e.g., SAE percentage) as reporting gaps, but these do not undermine the main conclusions. No erratum is warranted for the core results, though the authors should consider issuing a data availability statement and clarifying the SAE percentage discrepancy.

1.
HIGHdata code
Add a data availability statement to the manuscript (e.g., in the Methods or a dedicated section) specifying how de-identified individual participant data can be accessed, such as via a managed access committee or a repository like ClinicalStudyDataRequest.
The paper currently lacks a data availability statement, which is a key reporting requirement for clinical trials and a common reason for reader concern about reproducibility.
2.
HIGHdata code
Deposit the statistical analysis code (e.g., Stata do-files) in a public repository such as Zenodo with a DOI, and reference it in the manuscript.
Sharing analysis code enhances reproducibility and is a low-cost way to strengthen the paper's transparency.
3.
MEDIUMreporting
Clarify the dosing regimens for each investigational drug in the main text or supplement, as the current text implies but does not fully detail them.
Complete methods are essential for replication and for readers to assess the clinical applicability of the results.
4.
MEDIUMreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or acknowledgments, and provide a CONSORT checklist as supplementary material.
Explicitly confirming CONSORT adherence and providing the checklist helps readers verify reporting completeness.
5.
MEDIUMreporting
Clarify the regulatory compliance framework (e.g., Declaration of Helsinki) in the ethics section.
Explicitly naming the ethical framework strengthens the ethics reporting.
6.
MEDIUMreporting
Reconcile the discrepancy in the serious adverse event percentage between the abstract (3%) and Table 2 (3.2%) and ensure consistent reporting.
Internal inconsistencies, even minor, can undermine reader trust in the accuracy of the reported data.
7.
LOWcopyedit
Fix the missing space in the abstract: change '17,573copies/ml[5,549-55,700]' to '17,573 copies/ml [5,549-55,700]'.
Minor typographical errors detract from the paper's professionalism.
8.
LOWcopyedit
Standardize the protocol URL format in Methods, paragraph 2, to use a single consistent format (e.g., with or without 'http://').
Duplicate URL formats are a minor consistency issue.
9.
LOWcopyedit
Rephrase the sentence in Discussion, paragraph 4, for clarity: 'These findings, along with the additional benefits of smaller pill size, once-daily administration, lower cost, and lower risk of hypersensitivity, make TAF a valuable second-line option.'
Minor punctuation and phrasing improvements enhance readability.

Full text (36,566 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.

DOI

10.1056/NEJMoa2404597

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-22